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 2 
Abstract 6 
 7 
Hypothesis: Macrophage migration inhibitory factor plays an important role in the 8 
expression of interleukin (IL)-1β and the nucleotide-binding oligomerization 9 
domain-like receptor protein 3 (NLRP3) inflammasome in lipopolysaccharide-induced 10 
otitis media.  11 
Background: NLRP3 inflammasome and macrophage migration inhibitory factor are 12 
critical molecules mediating inflammation. However, the interaction between the 13 
NLRP3 inflammasome and macrophage migration inhibitory factor has not been fully 14 
examined.  15 
Methods: Wild-type mice and macrophage migration inhibitory factor gene-deficient 16 
(MIF-/-) mice received a transtympanic injection of either lipopolysaccharide or 17 
phosphate-buffered saline. The mice were sacrificed 24 h after the injection. 18 
Concentrations of IL-1β, NLRP3, ASC (apoptosis-associated speck-like protein 19 
containing a caspase recruitment domain and a pyrin domain), and caspase-1 in the 20 
 3 
middle ear effusions were measured by enzyme-linked immunosorbent assay. Temporal 21 
bones were processed for histologic examination and immunohistochemistry.  22 
Results: In the immunohistochemical study using the wild-type mice, positive staining 23 
of macrophage migration inhibitory factor, NLRP3, ASC, and caspase-1 were observed 24 
in infiltrating inflammatory cells induced by lipopolysaccharide in the middle ear. The 25 
number of inflammatory cells caused by lipopolysaccharide administration decreased 26 
remarkably in the MIF-/- mice as compared with the wild-type mice. The concentrations 27 
of IL-1β, NLRP3, ASC, and caspase-1 increased in the lipopolysaccharide-treated 28 
wild-type mice. The MIF-/- mice with lipopolysaccharide had decreased levels of IL-1β, 29 
NLRP3, ASC, and caspase-1 as compared with the wild-type mice.  30 
Conclusion: Macrophage migration inhibitory factor has an important role in the 31 
production of IL-1β and the NLRP3 inflammasome. Controlling the inflammation by 32 
modulating macrophage migration inhibitory factor and the NLRP3 inflammasome may 33 
be a novel therapeutic strategy for otitis media.  34 
 35 
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Text 40 
 41 
Introduction 42 
 43 
Otitis media is one of the most common diseases, especially in children. Otitis 44 
media associated with bacterial infection is frequently treated with antibiotics all over 45 
the world (1). Repeated use of antibiotics for frequent recurrence of otitis media might 46 
be related to microbial antibiotic resistance (2). Multiple inflammatory mediators have 47 
been reported in the pathophysiology of otitis media, and regulation of these factors 48 
may become a novel therapeutic option for otitis media without the administration of 49 
antibiotics (3,4). Interleukin (IL)-1β is a pro-inflammatory cytokine with important 50 
roles in the innate immune system. IL-1β is involved in the pathogenesis of otitis media, 51 
and activated caspase-1 is required for the processing of pro-IL-1β into mature IL-1β 52 
(3).  53 
The inflammasome is a protein complex, and several subtypes of 54 
inflammasome have been reported. The nucleotide-binding oligomerization domain 55 
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(NOD)-like receptor protein 3 (NLRP3) inflammasome is an important inflammatory 56 
factor discovered at the beginning of the 2000s (5,6). The components of the NLRP3 57 
inflammasome are NLRP3, ASC (adaptor apoptosis-associated speck-like protein 58 
containing a caspase activation and recruitment domain (CARD) and a pyrin domain 59 
(PYD)), and pro-caspase-1 (7). The NLRP3 inflammasome controls the production of 60 
IL-1β and IL-18 in collaboration with Toll-like receptors and nuclear factor kappa B 61 
(NF-κB). When the NLRP3 inflammasome is formed, it causes caspase-1 activation, 62 
resulting in the maturation of IL-1β (8). The role of the NLRP3 inflammasome has been 63 
extensively examined in numerous diseases, and has also been reported as a critical 64 
factor controlling inflammation in otitis media, both in human and animal models 65 
(9-12).  66 
Macrophage migration inhibitory factor is an inflammatory and 67 
stress-regulating cytokine with multiple functions (13). The significant role of 68 
macrophage migration inhibitory factor in middle ear and inner ear diseases has been 69 
reported (14-19). The reduction in macrophage migration inhibitory factor activity by 70 
intraperitoneal injection of a macrophage migration inhibitory factor antagonist can 71 
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decrease inflammatory responses in the middle ear cavity in lipopolysaccharide-induced 72 
otitis media (20). The inhibition of macrophage migration inhibitory factor pathway 73 
reduces cytokine production (13). However, the mechanism of inflammation through 74 
macrophage migration inhibitory factor has not been fully revealed.  75 
To the best of our knowledge, only two recent studies have reported the 76 
interaction between the NLRP3 inflammasome and macrophage migration inhibitory 77 
factor (21,22). In addition, no previous study has shown the role of macrophage 78 
migration inhibitory factor in expression of the NLRP3 inflammasome in otitis media. 79 
Using macrophage migration inhibitory factor-deficient (MIF-/-) mice, the purpose of 80 
this study is to reveal the definitive effect of macrophage migration inhibitory factor in 81 
the induction of the NLRP3 inflammasome in lipopolysaccharide-induced otitis media.  82 
 83 
Materials and Methods  84 
 85 
Induction of otitis media by lipopolysaccharide 86 
 Male BALB/c mice at 6-10 weeks of age were used in this study. Through 87 
 8 
targeted disruption of the macrophage migration inhibitory factor gene, MIF-/- mice in 88 
the BALB/c background were established (23). The study was performed in accordance 89 
with the relevant animal protection rules, and the Animal Research Control Committee 90 
approved the study (application number, OKU-2016541; the name of the principal 91 
investigator, S.K.). Before the experiment, an otoscopic examination was performed on 92 
the ears of all the mice to ensure that the tympanic membranes were normal and that no 93 
middle ear inflammation was present. An intraperitoneal injection of a mixture of 94 
ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight) was 95 
administered for anesthesia during all experimental procedures. Both the wild-type mice 96 
and MIF-/- mice were randomly divided into two groups. The otitis media group 97 
received lipopolysaccharide (1.0 mg/mL; 10 μl/ear; both ears in each mouse; 98 
Sigma-Aldrich, St. Louis, Missouri, USA) via transtympanic injection using a 30-gauge 99 
needle. Phosphate-buffered saline (PBS) (10 μl/ear) was injected into both middle ears 100 
of the animals in the control group. The mice were sacrificed 24 hours after injection of 101 
the lipopolysaccharide or PBS. The middle ears were then washed transtympanically 102 
using 200 μl of PBS. The collected washings from the middle ear lavage were 103 
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centrifuged. The supernatant was transferred to microcentrifuge tubes (Treff AG, 104 
Degersheim, Switzerland) and stored at -30°C until analysis. The temporal bones were 105 
removed immediately after sacrifice and processed for histologic examination.  106 
 107 
Levels of IL-1β, NLRP3, ASC, and caspase-1 108 
The concentrations of IL-1β, NLRP3, ASC, and caspase-1 in the supernatant 109 
of the middle ear lavage (otitis media group, n=6; control group, n=6) were measured 110 
using enzyme-linked immunosorbent assay (ELISA) (IL-1β, 559603, BD OptEIA 111 
Mouse IL-1β ELISA Set, BD Biosciences, San Jose, CA, USA; NLRP3, 112 
CSB-EL015871MO, Mouse NLRP3 ELISA Kit, CUSABIO, College Park, MD, USA; 113 
ASC, CSB-EL019114MO, Mouse Apoptosis-associated speck-like protein containing a 114 
CARD (PYCARD) ELISA kit, CUSABIO; Caspase-1, SEB592Mu, ELISA Kit for 115 
Caspase 1, Cloud-Clone Corp., Houston, TX, USA). All samples were examined in 116 
duplicate, and measured values were averaged. 117 
 118 
Histologic examination 119 
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Temporal bone specimens from both the wild-type mice and MIF-/- mice 120 
(otitis media group, n=4; control group, n=4) were placed in 4% paraformaldehyde for 121 
72 hours and decalcified in 10% ethylenediaminetetraacetic acid for 3 weeks at 4°C. 122 
After dehydration, the specimens were embedded in paraffin and sectioned at a 123 
thickness of 10 μm, then mounted on glass slides, processed using hematoxylin and 124 
eosin staining, and evaluated under light microscopy. 125 
 126 
Immunohistochemistry 127 
The paraffin-embedded temporal bone specimens from the wild-type mice 128 
(otitis media group, n=6; control group, n=6) were sectioned at a thickness of 4 μm and 129 
mounted on glass slides. The sections were deparaffinized and rehydrated. Endogenous 130 
peroxidase activity was quenched with 0.3% hydrogen peroxide in methanol for 30 131 
minutes at room temperature. Antigen retrieval was performed by microwave heating. 132 
Goat serum albumin (S-1000, Vector Laboratories Inc., Burlingame, CA, USA) was 133 
used for 1 hour at room temperature to block non-specific protein binding. Rabbit 134 
anti-macrophage migration inhibitory factor antibody (sc-20121; Santa Cruz 135 
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Biotechnology, Inc., Santa Cruz, CA), rabbit anti-NLRP3 antibody (bs-10021R, Bioss 136 
Antibodies Inc., Woburn, MA, USA), rabbit anti-ASC antibody (NBP1-78977, Novus 137 
Biologicals, Littleton, CO, USA), and rabbit anti-caspase-1 antibody (NB100-56564, 138 
Novus Biologicals) were applied overnight at 4°C as the primary antibodies for 139 
immunohistochemical staining. Rabbit Immunoglobulin Fraction (X0903, Dako, 140 
Glostrup, Denmark) was used as a negative control. For visualization, a VECTASTAIN 141 
Elite ABC Kit (PK-6100, Vector Laboratories Inc.) and 3,3’-diaminobenzidine (DAB) 142 
reagent (K3467, Dako) were used according to the manufacturers’ instructions.  143 
The reaction was assessed by blinded investigators under light microscopy 144 
according to the method of previous study (24). Briefly, the rating score was classified 145 
as: (-), no positive reaction; (+), 1-10 positive cells; (++), 11-100 positive cells; and 146 
(+++), over 100 positive cells per high power field (×400). 147 
 148 
Statistical analysis 149 
 Data are presented as median ± standard error. For statistical analysis, the 150 
non-parametric Mann-Whitney U test was used for comparison of continuous variables 151 
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between the two groups. The chi-square test was applied to compare categorical 152 
variables. Significant differences were established at a level of P < 0.05 (IBM SPSS 153 
Statistics; IBM, New York, USA). 154 
 155 
Results  156 
 157 
Expression of macrophage migration inhibitory factor and NLRP3 inflammasome by 158 
lipopolysaccharide 159 
Lipopolysaccharide is a component of the outer membrane of gram-negative 160 
bacteria that is a major causative pathogen of otitis media, and it is a potent 161 
inflammatory molecule (14). Lipopolysaccharide induces an increased infiltration of 162 
inflammatory cells in middle ear (25). As a first step, we examined the expression and 163 
localization of macrophage migration inhibitory factor, NLRP3, ASC, and caspase-1 in 164 
the middle ear cavity as induced by lipopolysaccharide in wild-type mice.  165 
Strong positive immunostaining was found for macrophage migration 166 
inhibitory factor in the infiltrating inflammatory cells as well as mucosal epithelium in 167 
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the middle ear of the lipopolysaccharide-injected wild-type mice. NLRP3, ASC, and 168 
caspase-1 were also observed in inflammatory cells and middle ear mucosa of the 169 
lipopolysaccharide-treated wild-type mice. There was no significant immunostaining in 170 
the middle ear in the negative controls using Rabbit Immunoglobulin Fraction in the 171 
PBS-treated wild-type mice (Figure 1).  172 
The rating scores of immunopositive cells for macrophage migration 173 
inhibitory factor, NLRP3, ASC, and caspase-1 were summarized in Table 1. The 174 
lipopolysaccharide-injected wild-type mice had the increased number of 175 
immunopositive cells as compared with PBS-injected control mice (macrophage 176 
migration inhibitory factor, P<0.05; NLRP3, P<0.05; ASC, P<0.05; caspase-1, P<0.05).  177 
 178 
Role of macrophage migration inhibitory factor in lipopolysaccharide-induced otitis 179 
media 180 
Next, we examined the effect of deficiency of the macrophage migration 181 
inhibitory factor gene in lipopolysaccharide-induced otitis media. Administration of 182 
lipopolysaccharide into the middle ear cavity induced remarkable infiltration of 183 
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inflammatory cells (polymorphonuclear leukocyte and monocyte) in the middle ear in 184 
wild-type mice (Figure 2A). In contrast, a small number of infiltrating inflammatory 185 
cells was detected in the middle ear in lipopolysaccharide-treated MIF-/- mice (Figure 186 
2B). No significant number of inflammatory cells was found in the middle ear in either 187 
the wild-type mice or MIF-/- mice in the PBS-injected control group. 188 
 189 
Quantification of IL-1β and NLRP3 inflammasome 190 
The histological findings showed the inflammatory response reduced in MIF-/- 191 
mice by lipopolysaccharide as compared with wild type mice. Thus, we examined the 192 
levels of IL-1β, NLRP3, ASC, and caspase-1 in lipopolysaccharide-induced otitis media. 193 
The protein levels of IL-1β, NLRP3, ASC, and caspase-1 in the supernatant of the 194 
middle ear lavage from both the wild-type mice and MIF-/- mice are shown in Figure 3.  195 
Compared with the PBS-injected wild-type mice, the 196 
lipopolysaccharide-injected wild-type mice showed a significant increase in the protein 197 
concentration of IL-1β in the middle ear (P < 0.05). In the MIF-/- mice, 198 
lipopolysaccharide induced a lower level of IL-1β than in the wild-type mice. There was 199 
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a significant difference in the concentration of IL-1β between the lipopolysaccharide 200 
group and PBS group of MIF-/- mice (Figure 3).  201 
Compared with the PBS-injected wild-type mice, the 202 
lipopolysaccharide-injected wild-type mice showed significant up-regulation of NLRP3 203 
(P < 0.05), ASC (P < 0.05), and caspase-1 (P < 0.05) in the middle ear. There were 204 
significant differences between the wild-type mice and MIF-/- mice in the concentrations 205 
of NLRP3 (P < 0.05), ASC (P < 0.05), and caspase-1 (P < 0.05) induced by 206 
lipopolysaccharide. In addition, no statistically significant difference was observed in 207 
the concentrations of NLRP3, ASC, and caspase-1 between the lipopolysaccharide 208 
group and PBS group of MIF-/- mice (Figure 3).  209 
 210 
Discussion 211 
 212 
Otitis media is one of the most common middle ear diseases, and patients with 213 
otitis media frequently have hearing impairment. Numerous factors are associated with 214 
the onset and development of otitis media. The presence of upper respiratory diseases 215 
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and Eustachian tube dysfunction are important factors, and inflammatory cytokines and 216 
chemokines including IL-1β are also involved in the pathogenesis of otitis media (3).  217 
Lipopolysaccharide from gram-negative bacteria activates Toll-like receptor 4, 218 
and induces IL-1β production through the NF-κB pathway (26). In addition, the 219 
maturation of pro-IL-1β protein into the secreted bioactive form of IL-1β requires a 220 
second signal via NLRP3 inflammasome (27). Lipopolysaccharide has been detected in 221 
the middle ear in almost all patients with otitis media (17). The expression of Toll-like 222 
receptor 4 in the middle ear tissues of patients with otitis media has been reported, and 223 
Toll-like receptors have been suggested to have an important role in the pathogenesis of 224 
otitis media (4,28,29). Recent studies have reported that NLRP3 was detected in middle 225 
ear tissues in patients with otitis media (9,11). In an animal model of otitis media, the 226 
NLRP3 inflammasome was induced by lipopolysaccharide in mouse middle ear, and 227 
ASC-deficient mice had reduced middle ear inflammation (10,12).  228 
Macrophage migration inhibitory factor is a cytokine expressed in various 229 
cells, and has been associated with a multitude of diseases (30). Macrophage migration 230 
inhibitory factor has been reported to have a possible role in middle ear diseases and 231 
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hearing function (14,19). Inhibition of macrophage migration inhibitory factor resulted 232 
in the reduction of inflammatory responses in experimental otitis media (20). However, 233 
the mechanism was not revealed. This study shows for the first time that production of 234 
IL-1β and the NLRP3 inflammasome by lipopolysaccharide is remarkably suppressed in 235 
MIF-/- mice. There were several limitations in this study including small sample size and 236 
the use of a single time point. However, our findings suggest that the reduced 237 
inflammation in histological findings and the decreased secretion of IL-1β in MIF-/- 238 
mice are the result of down-regulation of the NLRP3 inflammasome.  239 
Investigations are just starting to examine the relationship between 240 
macrophage migration inhibitory factor and the NLRP3 inflammasome. A recent study 241 
showed that macrophage migration inhibitory factor is required for the interaction 242 
between NLRP3 and the intermediate filament protein vimentin, which is critical for 243 
NLRP3 activation (22). Another study showed that macrophage migration inhibitory 244 
factor has an upstream role in the inflammatory pathway by regulating NLRP3 245 
inflammasome activation (21). The possible mechanism of macrophage migration 246 
inhibitory factor and NLRP3 inflammasome on the induction of IL-1β is shown in 247 
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Figure 4. In this study, the concentration of IL-1β induced in the middle ear by 248 
lipopolysaccharide was low in the MIF-/- mice as compared with the wild-type mice. 249 
Down-regulation of the caspase-1 may be the major factor in the reduced production of 250 
IL-1β in the MIF-/- mice. However, there was still a significant difference in the 251 
expression of IL-1β between the lipopolysaccharide-injected MIF-/- mice and 252 
PBS-injected MIF-/- mice. Lipopolysaccharide may also induce IL-1β through a 253 
different signaling pathway independent of macrophage migration inhibitory factor and 254 
the NLRP3 inflammasome.  255 
Otitis media is a common disease, and the management of intractable otitis 256 
media is a challenging problem. Macrophage migration inhibitory factor and NLRP3 257 
inflammasome have an important role in immune response. For example, the inhibition 258 
of macrophage migration inhibitory factor activity attenuated lethality in endotoxic 259 
shock (31). In addition, macrophage migration inhibitory factor genetic variants are a 260 
clinically important risk factor for the development of several diseases (32). Currently, 261 
there is no clinically available targeted therapy that can effectively inhibit macrophage 262 
migration inhibitory factor and/or NLRP3 inflammasome. However, macrophage 263 
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migration inhibitory factor as well as NLRP3 inflammasome may be promising factors 264 
in future treatment strategies for otitis media.  265 
In summary, the expression of IL-1β is markedly induced by 266 
lipopolysaccharide in mouse middle ear, and is significantly suppressed in MIF-/- mice 267 
as compared with wild-type mice. The induction of NLRP3 inflammasome by 268 
lipopolysaccharide is also reduced in the MIF-/- mice. Our findings suggest that 269 
regulation of macrophage migration inhibitory factor and the NLRP3 inflammasome 270 
may become a new therapeutic target for control of the inflammation from a different 271 
point of view.  272 
 273 
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Figure Captions  374 
 375 
Figure 1 376 
Immunohistochemical staining for (A) macrophage migration inhibitory factor, (B) 377 
nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), (C) 378 
apoptosis-associated speck-like protein containing a caspase recruitment domain and a 379 
pyrin domain (ASC), and (D) caspase-1 in lipopolysaccharide-injected wild-type mice. 380 
Strong positive staining (brown color) was observed in inflammatory cells (black arrow). 381 
(E) Immunohistochemical staining using Rabbit Immunoglobulin Fraction in 382 
phosphate-buffered saline (PBS)-treated control mice. (*, middle ear cavity; Scale bar, 383 
100 μm)  384 
 385 
Figure 2 386 
Histological findings of the middle ear cavity in (A) wild-type mice and (B) MIF-/- mice 387 
with transtympanic injection of lipopolysaccharide. Numerous inflammatory cells 388 
(polymorphonuclear leukocyte and monocyte) infiltrated into the middle ear cavity in 389 
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the lipopolysaccharide-injected wild-type mice. In contrast, a small number of 390 
inflammatory cells were found in the lipopolysaccharide-injected MIF-/- mice. 391 
(Hematoxylin and eosin staining; scale bar, 100 μm) (black arrow, inflammatory cells; *, 392 
middle ear cavity; MIF, macrophage migration inhibitory factor).  393 
 394 
Figure 3 395 
Concentrations of (A) interleukin-1β (IL-1β), (B) nucleotide-binding oligomerization 396 
domain-like receptor protein 3 (NLRP3), (C) apoptosis-associated speck-like protein 397 
containing a caspase recruitment domain and a pyrin domain (ASC), and (D) caspase-1 398 
in lipopolysaccharide (LPS)-injected and phosphate-buffered saline (PBS)-treated mice. 399 
(n = 6 (12 ears); median ± standard error; *, P < 0.05) (MIF, macrophage migration 400 
inhibitory factor; n.s., not significant).  401 
 402 
Figure 4 403 
Potential molecular mechanism of macrophage migration inhibitory factor and NLRP3 404 
inflammasome on the production of IL-1β. Signal 1 (Toll like receptor/NF-κB pathway) 405 
 30 
is needed to induce pro-IL-1β. Signal 2 with macrophage migration inhibitory factor, 406 
vimentin, and NLRP3 inflammasome has a critical role in the production of caspase-1. 407 
The active caspase-1 released from the NLRP3 inflammasome is responsible for the 408 
conversion of inactive IL-1β precursor into its biological active form.  409 
LPS: lipopolysaccaride 410 
TLR4: Toll-like receptor 4 411 
NF-κB: nuclear factor-kappa B 412 
NLRP3: the nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 413 
ATP: adenosine triphosphate 414 
PAMPs: pattern-associated molecular patterns 415 
DAMPs: danger-associated molecular patterns 416 
ROS: reactive oxygen species 417 
MIF: macrophage migration inhibitory factor 418 
ASC: adaptor apoptosis-associated speck-like protein containing a caspase activation 419 
and recruitment domain (CARD) and a pyrin domain (PYD) 420 
 421 
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Figure 2 Click here to access/download;Figure (TIFF, PDF, Word Doc,
PPT, or EPS files are acceptable);Fig 2.tif
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Table 1: The rating scores of immunostaining for each protein in lipopolysaccharide 
(LPS)- or phosphate buffered saline (PBS)-injected wild-type mice.   
 
 MIF NLRP3 ASC Caspase-1 
score LPS 
(n=6) 
PBS 
(n=6) 
LPS 
(n=6) 
PBS 
(n=6) 
LPS 
(n=6) 
PBS 
(n=6) 
LPS 
(n=6) 
PBS 
(n=6) 
- 0 0 0 0 0 1 0 0 
+ 0 6 0 5 0 5 0 6 
++ 1 0 1 1 1 0 2 0 
+++ 5 0 5 0 5 0 4 0 
 
The rating score: (-), no positive reaction; (+), 1-10 positive cells; (++), 11-100 positive 
cells; and (+++), over 100 positive cells per high power field (×400). 
 
MIF, macrophage migration inhibitory factor 
NLRP3, The nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 
ASC, adaptor apoptosis-associated speck-like protein containing a caspase activation 
and recruitment domain (CARD) and a pyrin domain (PYD) 
 
 
Table 1
